These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9684757)

  • 41. Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.
    Sonmez M; Saglam F; Karahan SC; Erkut N; Mentese A; Sonmez B; Ucar F; Topbas M; Ovali E
    Hematology; 2010 Dec; 15(6):391-6. PubMed ID: 21114901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
    Bellucci S; Ignatova E; Jaillet N; Boffa MC
    Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
    Ahlstrand E; Samuelsson J; Lindgren M; Pettersson H; Liljeholm M; Ravn-Landtblom A; Scheding S; Andréasson B
    Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera.
    Wieczorek I; MacGregor IR; Prescott RJ; Ludlam CA
    Blood Coagul Fibrinolysis; 1992 Dec; 3(6):823-6. PubMed ID: 1489903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
    Taylor FB; Müller-Eberhard HJ
    J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A history of early stent thrombosis is associated with prolonged clot lysis time.
    Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
    Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
    Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
    Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PAI-1 inhibition enhances the lysis of the platelet-rich part of arterial-like thrombi formed in vitro. A comparative study using thrombi prepared from rat and human blood.
    van Giezen JJ; Nerme V; Abrahamsson T
    Blood Coagul Fibrinolysis; 1998 Jan; 9(1):11-8. PubMed ID: 9607114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.
    Eitzman DT; Fay WP; Lawrence DA; Francis-Chmura AM; Shore JD; Olson ST; Ginsburg D
    J Clin Invest; 1995 May; 95(5):2416-20. PubMed ID: 7738206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clot retraction facilitates clot lysis.
    Carroll RC; Gerrard JM; Gilliam JM
    Blood; 1981 Jan; 57(1):44-8. PubMed ID: 7448414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.
    Pósfai É; Marton I; Borbényi Z; Nemes A
    Anatol J Cardiol; 2016 Jun; 16(6):397-402. PubMed ID: 27182615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.
    Villmow T; Kemkes-Matthes B; Matzdorff AC
    Thromb Res; 2002 Nov; 108(2-3):139-45. PubMed ID: 12590950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
    Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
    Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi.
    Fay WP; Murphy JG; Owen WG
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1277-84. PubMed ID: 8857925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera.
    Allegra A; Alonci A; Bellomo G; Campo S; Cannavò A; Penna G; Russo S; Centorrino R; Gerace D; Petrungaro A; Musolino C
    Leuk Lymphoma; 2011 Jan; 52(1):101-7. PubMed ID: 21133718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.